Plus   Neg

Sanofi Agrees To Buy Synthorx For $2.5 Bln - Quick Facts

French drug maker Sanofi (SNYNF,SNY) announced Monday that it has agreed to acquire Synthorx, Inc. (THOR), a clinical-stage biotechnology company, for $68 per share in cash. The deal represents an aggregate equity value of about $2.5 billion.

The transaction was unanimously approved by both the Sanofi and Synthorx Boards of Directors.

Under the deal terms, Sanofi will commence a cash tender offer to acquire Synthorx stock for $68 per share in cash. The per share acquisition price represents a 172% premium to Synthorx's closing price on December 6.

The tender offer is expected to commence in December 2019, and the acquisition is expected to complete in the first quarter of 2020. Following the successful completion of the tender offer, a Sanofi unit will merge with Synthorx. Sanofi plans to finance the transaction with cash on hand.

Synthorx is focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders.

John Reed, Global Head of Research & Development at Sanofi, said, "Synthorx's exceptionally novel discovery platform has already produced a molecule that has the potential to become a foundation of the next generation of immuno-oncology combination therapies. By selectively expanding the numbers of effector T-cells and natural killer cells in the body, THOR-707 can be combined with our current oncology medicines and our emerging pipeline of immuno-modulatory agents for treating cancer."

Reed also noted that Synthorx's pipeline of engineered lymphokines has great promise not only for oncology but also for addressing many autoimmune and inflammatory diseases.

Morgan Stanley & Co. is acting as financial advisor to Sanofi and Centerview Partners LLC is acting as exclusive financial advisor to Synthorx.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Swiss drug major Novartis AG reported Wednesday that its fourth-quarter net profit declined, while operating income climbed on strong sales growth. Looking ahead, for fiscal 2020, the company expects net sales to grow mid to high-single digit and core operating income to grow high-single to low double digit, both in constant currency. Starbucks on Tuesday said it has closed more than half of its stores in China temporarily due to the worsening coronavirus outbreak that claimed around 132 lives in the country. The coffee giant is also monitoring and modifying the operating hours of all of its stores in the region.The closed store count would be more than 2000 as Starbucks operates almost 4,300 outlets in China. eBay Inc. (EBAY) Wednesday reported a fourth-quarter profit that trumped Wall Street analysts' estimates, as did revenues. However, shares of the company slipped over 5% after the company issued a weak outlook for the first quarter. eBay's fourth-quarter profit dropped to $558 million or $0.69 per...
Follow RTT